To recover your password please fill in your email address
Please fill in below form to create an account with us
DREAM3R – DuRvalumab (MEDI4736) with chEmotherapy as first line treAtment in advanced pleural Mesothelioma - A phase 3 Randomised trial
|
Trial Summary: |
To determine the effectiveness of adding durvalumab to standard first line chemotherapy with cisplatin and pemetrexed in advanced pleural mesothelioma, and to identify potential and prognostic biomarkers from blood and tissue. |
|
Supported By: |
Astra Zeneca |
|
Eligibility: |
Adults commencing first-line systemic treatment for unresectable epithelioid pleural mesothelioma. |
|
Registration ID: |
NCT04334759 |
|
Participation: |
Australia, New Zealand, USA |
|
Status: |
Recruiting |
|
Activation Date: |
3rd Feb 2021 |
|
Chairs: |
Prof Anna Nowak |
|
Contact: |